my personal edition > psychiatry other > news


  E-Mail this DGNews to a colleague

DGNews

Alliant Pharmaceuticals Announces Return of Chewable Tablets for ADHD

Treatment includes chewable tablets and oral solution

ALPHARETTA, G.A. -- June 6, 2006 -- Alliant Pharmaceuticals, Inc., a leading pediatric specialty pharmaceutical company, today announced the re-introduction of Methylin Chewable Tablets (methylphenidate HCL).

The product is the first, and only, chewable tablet for use in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in children.

Methylin is considered the gold standard for treating children for ADHD. ADHD is a disorder of the brain in which the individual repeatedly exhibits inappropriate impulsivity and/or inattention. According to the Attention Deficit Disorder Association, an estimated 5-10 percent of school age children, and an estimated 3-6 percent of adults suffer from ADHD.

Studies show that more than 50% of children ages 12 and under have difficulty swallowing tablets and capsules. "We are excited to have both Methylin Chewable Tablets and Methylin Oral Solution available for physicians to help improve patient compliance," stated Mark Pugh, President and CEO of Alliant. "Each of these medications was designed specifically to help improve efficacy in treatment."

Alliant voluntarily removed the Methylin Chewable Tablets from the market in February 2005 after its manufacturer, Mallinckrodt, discovered a blending issue in the manufacturing process that could affect dosage potency. Pugh adds that the manufacturing issue was resolved and no further issues exist.

Methylin Chewable Tablets are available in a 2.5mg, 5mg and 10mg dose. The Methylin Oral Solution is available in a 5mg / 5mL and 10mg / 5mL dose.


SOURCE: Alliant Pharmaceuticals, Inc.

E-Mail this DGNews to a colleague

To print, use this version